

Selected High Risk Medications to Avoid in Patients Aged 65 Years or Older.

For more detailed information access the following link <http://www.healthfirst.org/HRM>

Drugs to Avoid ^{a,1}	Concern ¹	Potential Alternatives ^b
Antidepressants, tricyclic (eg, amitriptyline, clomipramine, doxepin at >6 mg/day)	Highly anticholinergic, sedating, and causes orthostatic hypertension	For depression: pharmacotherapy with SSRI (citalopram, escitalopram, sertraline), SNRI (venlafaxine), or others (bupropion, duloxetine) can be selected based on adverse effect profiles, cost, and patient preferences. Consider psychotherapy, ECT, or light therapy. ²
Antihistamines, first generation (eg, clemastine, hydroxyzine, promethazine)	Potent anticholinergic properties; may cause sedation, constipation, dry mouth, and impair cognitive performance; clearance reduced in advanced age	OTC second generation antihistamines (eg, cetirizine, fexofenadine, loratadine); third generation antihistamines (eg, levocetirizine). For allergic rhinitis: intranasal corticosteroids. ³ For emesis: consider ondansetron.
Anti-infectives - Nitrofurantoin	Potential for pulmonary toxicity; lack of efficacy in patients with CrCl <60 mL/min due to inadequate drug concentration in the urine	For uncomplicated cystitis: antibiotic therapy may include fluoroquinolones or TMP-SMX. Consider patient's allergy history and other risk factors and local resistance patterns. ⁴
Antiparkinsonian agents - Benztropine (oral) - Trihexyphenidyl	Highly anticholinergic. Not recommended for prevention of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson's disease	For antipsychotic induced EPS the cornerstones of treatment are prevention, early detection, and management of potentially reversible causes. For Parkinson's disease: carbidopa/levodopa (+/- COMT Inhibitors), dopamine agonists, MAO B inhibitors. ⁶
Barbiturates (eg, phenobarbital)	High rate of physical dependence; tolerance to sleep benefits develops; risk of overdose at low dosages	For epilepsy: consider newer anti-epileptic drugs (eg, lamotrigine, topiramate). ⁷
Benzodiazepines, short-, intermediate-, and long-acting (eg, clonazepam, diazepam, lorazepam)	Older adults have increased sensitivity to benzodiazepines and slower metabolism of long-acting agents. In general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle accidents in older adults	For anxiety: consider buspirone, SSRIs, SNRIs, and/or CBT. ⁸
Cardiovascular agents - Methyldopa - Digoxin >0.125 mg/day	High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension In heart failure, high dosages are associated with no additional benefit; decreased clearance may lead to risk of toxic effects	Consider alternate antihypertensive therapy (eg, thiazide diuretic, ACEI, ARBs, long-acting dihydropyridine calcium channel blockers). ⁹ Consider rate control before rhythm control; monitor SCr and digoxin levels.
Endocrine agents - Megestrol	Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults	Maximize nutritional supplementation. Consider mirtazapine for weight gain. ¹⁰
Estrogens +/- progestin, oral and patches (eg, Premarin, PremPro, Vivelle Dot)	Lack of cardioprotective effect in older women; carcinogenic potential (breast and endometrium)	For osteoporosis: non-estrogen treatments (eg, calcium and vitamin D supplementation or bisphosphonates) For continuing perimenopausal symptoms: reassess need to treat. ¹¹

Nonbenzodiazepine hypnotics (eg, eszopiclone, zolpidem)	Similar adverse effects to benzodiazepines in older adults (eg, delirium, falls, fractures); minimal improvement in sleep latency and duration	Nonpharmacologic therapy (eg, avoid daytime naps and caffeinated beverages, and other sleep hygiene techniques) ¹²
Non-COX-selective NSAIDs - Indomethacin - Ketorolac	Increases risk of GI bleeding and peptic ulcer disease in high-risk groups ²	Consider a COX-2 selective NSAID (eg, celecoxib) or concomitant gastrointestinal prophylaxis with a PPI in patients with risk factors for bleeding. ¹³
Skeletal muscle relaxants (eg, carisoprodol, cyclobenzaprine, metaxalone, methocarbamol)	Poorly tolerated because of anticholinergic adverse effects, sedation, and weakness; effectiveness at doses tolerated by older patients is questionable ²	For muscle spasms: nonpharmacologic therapy (eg, physiotherapy, heat or cold, and TENS); short-term acetaminophen, ibuprofen, or naproxen for pain. ¹⁴
Sulfonylureas, long-acting - Chlorpropamide - Glyburide	Greater risk of severe prolonged hyperglycemia in older adults ²	Consider glipizide or metformin. ¹⁵

a Including combination products, if available.

b Refer to a patient's individual plan formulary to determine whether a potential alternative may be covered.

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CBT = cognitive-behavioral therapy; CNS = central nervous system; COX = cyclooxygenase; ECT = electroconvulsive therapy; EPS = extrapyramidal symptoms; GI = gastrointestinal; MAO-B = monoamine oxidase B; NSAID = nonsteroidal anti-inflammatory drug; OTC = over-the-counter; PPI = proton pump inhibitor; SCr = serum creatinine; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TENS = transcutaneous electrical stimulation; TMP-SMX = trimethoprim-sulfamethoxazole.

References: 1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2012;60(4):616-631. 2. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2008;149(10):725-733. 3. American Academy of Allergy, Asthma & Immunology. The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol.* 2008;122:S1-S84. 4. Gilbert DN, Moeller RC Jr, Eliopoulos GM, Chambers HF, Saag MS, eds. *The Sanford Guide to Antimicrobial Therapy*: 2011. 41st ed. Sperryville, VA: Antimicrobial Therapy, Inc; 2011. 5. Jibson MD. Second-generation antipsychotic medications: pharmacology, administration, and comparative side effects. Marder S, section ed, Hermann R, deputy ed. http://www.uptodate.com/contents/second-generation-antipsychotic-medications-pharmacology-administration-and-comparative-side-effects?source=search_result&search=second+generation+antipsychotic+medications+pharmac&selectedTitle=7%7E150. UpToDate Web site. Updated June 3, 2011. Accessed August 1, 2012. 6. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2002; 58:11-17. 7. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology* 2004;62:1252 <http://www.neurology.org/content/62/8/1252.full.pdf>. Current as of July 31, 2012. Accessed July 31, 2012. 8. Wetherell JL, Lenze EJ, Stanley MA. Evidence-based treatment of geriatric anxiety disorders. *Psychiatr Clin North Am.* 2005;28(4):871-896. 9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA.* 2003;289(19):2560-2572. 10. Ritchie C. Geriatric nutrition: nutritional issues in older adults. UpToDate, Schmadee, KE, Lipman, TO, section eds, Sokol HN, deputy ed. UpToDate Web site. <http://www.uptodate.com/contents/geriatric-nutrition-nutritional-issues-in-older-adults?vi>. Updated February 10, 2012. Accessed August 1, 2012. 11. National Osteoporosis Foundation. *Clinician's Guide to Prevention and Treatment of Osteoporosis*. Washington, DC: National Osteoporosis Foundation; 2010. http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf. Accessed May 18, 2011. 12. McCurry SM, Logsdon RG, Teri L, Vitiello MV. Evidence-based psychological treatments for insomnia in older adults. *Psychol Aging.* 2007;22:18. 13. Rostom A, Dube C, Wells GA, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database of Systematic Reviews* 2002, Issue 4. Art. No.: CD002296. DOI: 10.1002/14651858.CD002296. 14. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. *Can Med Assoc J.* 1997;156(3):385-391. 15. American Diabetes Association. Standards of medical care in diabetes—2012. *Diabetes Care.* 2012;35(suppl 1):S11-S63.